Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Blackstone follows Abingworth, but why?
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
